Advertisement

Spontaneous peritoneal drainage following paracentesis in a hospitalized patient with resolution of type 1 hepatorenal syndrome

      Abstract

      The hepatorenal syndrome develops in a small percentage of patients with advanced liver disease. The pathogenesis involves intravascular volume contraction secondary to pooling of blood in the splanchnic vessels, stimulation of the sympathetic nervous system and the renin–angiotensin–aldosterone pathway, and increased intra-abdominal pressure secondary to the formation of large volumes of ascitic fluid. The treatment options are limited, and liver transplant is the only definitive form of management. Here we suggest an alternative approach to treating hepatorenal syndrome based on the unexpected continuous peritoneal drainage in a 36-year-old man hospitalized with hepatic encephalopathy and hepatorenal syndrome. A total of 11.2 L ascitic fluid drained over 5 days from a paracentesis puncture site with marked improvement in renal function; the creatinine decreased from 3.3 mg/dL to 0.7 mg/dL and the BUN decreased from 42 mg/dL to 10 mg/dL. The discussion with this case report summarizes the pathogenesis, including the effect of intra-abdominal pressure, of the hepatorenal syndrome, outlines medical management, and makes a proposal for clinical study based on this case.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Simonetto DA
        • Gines P
        • Kamath PS.
        Hepatorenal syndrome: pathophysiology, diagnosis, and management.
        BMJ. 2020; 370: m2687https://doi.org/10.1136/bmj.m2687
        • Aithal GP
        • Palaniyappan N
        • China L
        • et al.
        Guidelines on the management of ascites in cirrhosis.
        Gut. 2021; 70: 9-29https://doi.org/10.1136/gutjnl-2020-321790
        • Allegretti AS
        • Ortiz G
        • Wenger J
        • et al.
        Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: a prospective cohort study.
        Int J Nephrol. 2015; 2015108139https://doi.org/10.1155/2015/108139
        • Angeli P
        • Ginès P
        • Wong F
        • et al.
        Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.
        J Hepatol. 2015; 62: 968-974https://doi.org/10.1016/j.jhep.2014.12.029
        • Baraldi O
        • Valentini C
        • Donati G
        • et al.
        Hepatorenal syndrome: Update on diagnosis and treatment.
        World J Nephrol. 2015; 4: 511-520https://doi.org/10.5527/wjn.v4.i5.511
        • China L
        • Freemantle N
        • Forrest E
        • et al.
        A randomized trial of albumin infusions in hospitalized patients with cirrhosis.
        N Engl J Med. 2021; 384: 808-817https://doi.org/10.1056/NEJMoa2022166
        • Esrailian E
        • Pantangco ER
        • Kyulo NL
        • et al.
        Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.
        Dig Dis Sci. 2007; 52: 742-748https://doi.org/10.1007/s10620-006-9312-0
        • El-Desoki Mahmoud EI
        • Abdelaziz DH
        • Abd-Elsalam S
        • et al.
        Norepinephrine is more effective than midodrine/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled Trial.
        Front Pharmacol. 2021; 12675948https://doi.org/10.3389/fphar.2021.675948
        • Saif RU
        • Dar HA
        • Sofi SM
        • et al.
        Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study.
        Indian J Gastroenterol. 2018; 37: 424-429https://doi.org/10.1007/s12664-018-0876-3
        • Facciorusso A
        • Chandar AK
        • Murad MH
        • et al.
        Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
        Lancet Gastroenterol Hepatol. 2017; 2: 94-102https://doi.org/10.1016/S2468-1253(16)30157-1
        • Wang H
        • Liu A
        • Bo W
        • et al.
        Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
        Medicine (Baltimore). 2018; 97: e0431https://doi.org/10.1097/MD.0000000000010431
        • Wong F
        • Pappas SC
        • Curry MP
        • et al.
        Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome.
        N Engl J Med. 2021; 384: 818-828https://doi.org/10.1056/NEJMoa2008290
        • Belcher JM
        • Parada XV
        • Simonetto DA
        • et al.
        Terlipressin and the treatment of hepatorenal syndrome: How the CONFIRM Trial moves the story forward.
        Am J Kidney Dis. 2021; https://doi.org/10.1053/j.ajkd.2021.08.016
        • Velez JC
        • Kadian M
        • Taburyanskaya M
        • et al.
        Hepatorenal acute kidney injury and the importance of raising mean arterial pressure.
        Nephron. 2015; 131: 191-201https://doi.org/10.1159/000441151
        • Mohmand H
        • Goldfarb S.
        Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome.
        J Am Soc Nephrol. 2011; 22: 615-621https://doi.org/10.1681/ASN.2010121222
        • Umgelter A
        • Reindl W
        • Wagner KS
        • et al.
        Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
        Crit Care. 2008; 12: R4https://doi.org/10.1186/cc6765
        • Umgelter A
        • Reindl W
        • Franzen M
        • et al.
        Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites.
        Intensive Care Med. 2009; 35: 152-156https://doi.org/10.1007/s00134-008-1253-y
        • Savino JA
        • Cerabona T
        • Agarwal N
        • Byrne D.
        Manipulation of ascitic fluid pressure in cirrhotics to optimize hemodynamic and renal function.
        Ann Surg. 1988; 208: 504-511https://doi.org/10.1097/00000658-198810000-00012
        • Chang Y
        • Qi X
        • Li Z
        • et al.
        Hepatorenal syndrome: insights into the mechanisms of intra-abdominal hypertension.
        Int J Clin Exp Pathol. 2013; 6: 2523-2528
        • Van Thiel DH
        • Moore CM
        • Garcia M
        • George M
        • Nadir A.
        Continuous peritoneal drainage of large-volume ascites.
        Dig Dis Sci. 2011; 56: 2723-2727https://doi.org/10.1007/s10620-011-1792-x
        • Martin DK
        • Walayat S
        • Jinma R
        • et al.
        Large-volume paracentesis with indwelling peritoneal catheter and albumin infusion: a community hospital study.
        J Community Hosp Intern Med Perspect. 2016; 6: 32421https://doi.org/10.3402/jchimp.v6.32421
        • Seethapathy H
        • Sharma S
        • Zhao S
        • et al.
        Acute kidney injury following paracentesis among inpatients with cirrhosis.
        Kidney Int Rep. 2020; 5: 1305-1308https://doi.org/10.1016/j.ekir.2020.05.014
        • Cade R
        • Wagemaker H
        • Vogel S
        • et al.
        Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function.
        Am J Med. 1987; 82: 427-438https://doi.org/10.1016/0002-9343(87)90442-6
        • Allegretti AS
        • Ortiz G
        • Cui J
        • et al.
        Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: a matched cohort analysis.
        Am J Kidney Dis. 2016; 68: 381-391https://doi.org/10.1053/j.ajkd.2016.02.041
        • Nadim MK
        • Kellum JA
        • Davenport A
        • et al.
        Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.
        Crit Care. 2012; 16: R23https://doi.org/10.1186/cc11188
        • Velez J.
        Patients with hepatorenal syndrome should be dialyzed?.
        Pro. Kidney. 2021; 360: 406-409
        • Yadav K
        • Serrano OK
        • Peterson KJ
        • et al.
        The liver recipient with acute renal dysfunction: A single institution evaluation of the simultaneous liver-kidney transplant candidate.
        Clin Transplant. 2018; 32https://doi.org/10.1111/ctr.13148
        • Chauhan K
        • Azzi Y
        • Faddoul G
        • et al.
        Pre-liver transplant renal dysfunction and association with post-transplant end-stage renal disease: A single-center examination of updated UNOS recommendations.
        Clin Transplant. 2018; 32: e13428https://doi.org/10.1111/ctr.13428
        • Fotopoulou C
        • Berg T
        • Hausen A
        • et al.
        Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites.
        BMC Palliat Care. 2019; 18: 109https://doi.org/10.1186/s12904-019-0497-3
        • Tapping CR
        • Ling L
        • Razack A.
        PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success.
        Br J Radiol. 2012; 85: 623-628https://doi.org/10.1259/bjr/24538524
        • Mercadante S
        • Intravaia G
        • Ferrera P
        • et al.
        Peritoneal catheter for continuous drainage of ascites in advanced cancer patients.
        Support Care Cancer. 2008; 16: 975-978https://doi.org/10.1007/s00520-008-0453-x
        • Caldwell J
        • Edriss H
        • Nugent K.
        Chronic peritoneal indwelling catheters for the management of malignant and nonmalignant ascites.
        Proc (Bayl Univ Med Cent). 2018; 31: 297-302https://doi.org/10.1080/08998280.2018.1461525
        • Velez JCQ
        • Petkovich B
        • Karakala N
        • et al.
        Point-of-care echocardiography unveils misclassification of acute kidney injury as hepatorenal syndrome.
        Am J Nephrol. 2019; 50: 204-211https://doi.org/10.1159/000501299